Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
The celebrations began with the unveiling of the Biocon Anthem
She will be responsible in this role for Finance & Controlling, HR Services and IT Management at Romaco Holding
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Subscribe To Our Newsletter & Stay Updated
